LCG
SUPN icon

Lisanti Capital Growth’s Supernus Pharmaceuticals SUPN Stock Holding History

Lisanti Capital Growth’s Portfolio SUPN Stock Details SUPN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-159,811
Closed -$5.79M – 169
2023
Q1 		$5.79M Sell
159,811
-223,449
-58% -$8.59M 0.81% 52
2022
Q4 		$13.7M Buy
383,260
+80
+0% +$2.78K 1.87% 8
2022
Q3 		$13M Sell
383,180
-33,470
-8% -$1.09M 1.73% 16
2022
Q2 		$12.1M Buy
416,650
+190,434
+84% +$5.45M 1.64% 19
2022
Q1 		$7.31M Sell
226,216
-78,239
-26% -$2.4M 0.82% 49
2021
Q4 		$8.88M Buy
+304,455
New +$9.24M 1.28% 21
2018
Q3 		– Sell
-60,670
Closed -$3.63M – 154
2018
Q2 		$3.63M Buy
60,670
+19,225
+46% +$996K 1.39% 17
2018
Q1 		$1.9M Buy
+41,445
New +$1.73M 0.92% 47
2017
Q4 		– Sell
-25,920
Closed -$1.04M – 129
2017
Q3 		$1.04M Sell
25,920
-42,715
-62% -$1.85M 0.65% 67
2017
Q2 		$2.96M Buy
68,635
+52,380
+322% +$1.86M 1.97% 5
2017
Q1 		$509K Sell
16,255
-27,535
-63% -$738K 0.73% 72
2016
Q4 		$1.11M Buy
43,790
+33,925
+344% +$758K 1.34% 30
2016
Q3 		$244K Sell
9,865
-27,305
-73% -$618K 0.31% 91
2016
Q2 		$757K Buy
+37,170
New +$659K 1.14% 37

Other funds holding SUPN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
SIMG
Stephens Investment Management Group Houston, Texas $7.3B AUM 41.96% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Lisanti Capital Growth's SUPN Position: Q2 2023 in Review

Lisanti Capital Growth sold out of Supernus Pharmaceuticals (SUPN) in Q2 2023, closing a stake of 159,811 shares — an estimated $5.79M sold.

Lisanti Capital Growth first reported a position in SUPN in Q2 2016 and held it in 14 quarters. The position peaked at $13.7M in Q4 2022. 249 funds tracked by Wall St. Rank hold SUPN as of Q2 2023.

  • Lisanti Capital Growth reported no remaining Supernus Pharmaceuticals position as of Q2 2023 after selling out during the quarter.
  • Lisanti Capital Growth sold 159,811 Supernus Pharmaceuticals shares in Q2 2023, an estimated $5.79M.
  • Lisanti Capital Growth first reported a position in Supernus Pharmaceuticals in Q2 2016 and held it in 14 quarters.
  • Lisanti Capital Growth's Supernus Pharmaceuticals position peaked at $13.7M in Q4 2022.
  • 249 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q2 2023.

Based on Lisanti Capital Growth's 13F filing for Q2 2023, filed 11 Aug 2023.